Enables mRNA 3'-UTR binding activity and mRNA base-pairing translational repressor activity. Involved in negative regulation of gene expression and regulation of pattern recognition receptor signaling pathway. Predicted to be part of RISC complex.
[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR708 mRNA
[Tretinoin co-treated with Phenylbutyrates co-treated with 1-hydroxy-2-oxo-3 and 3-bis(2-aminoethyl)-1-triazene] results in decreased expression of MIR708 mRNA
[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of MIR708 mRNA and [sodium arsenite results in increased abundance of arsenite] which results in increased expression of MIR708 mRNA
[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR708 mRNA
[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR708 mRNA
plastochromanol 8 promotes the reaction [resveratrol results in decreased expression of MIR708 mRNA] and resveratrol promotes the reaction [plastochromanol 8 results in decreased expression of MIR708 mRNA]
[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of MIR708 mRNA and [sodium arsenite results in increased abundance of arsenite] which results in increased expression of MIR708 mRNA
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000052684]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000052684]|See cases [RCV000052684]